ERBB2 and breast cancer: Before the advent of expression profiling, Harbeck et al (1999) and Zemzoum et al (2003) investigated urokinase-type plasminogen activator (uPA), and its inhibitor PAI-1 as prognostic factor for HER-2-positive breast cancer.